Jeff is a seasoned CEO with a proven track record at profitably growing emerging companies and business divisions. He has raised over $10M in seed capital from angel investors to start four different companies which he then led to becoming profitable or acquired. At his time at PCT as their COO he supported over 20 clinical trials in the Cell and Gene Therapy field. These trials ranged from Phase I to Phase III pivotal trials.
Former Chief Operating Officer of Progenitor Cell Therapy
Processed over 25 clinical trials for respective therapy customers
Responsible for tech transferring Kite’s T-Cell therapy out of the NIH, Novartis’ cell therapy out of U-Penn and Adaptimmume’s cell therapy out of U Penn
Cell processing / manufacturing experience that spans Phase I, II, & III therapies